

Name PRIYANKA SINGH
Date of Birth 29.06.1982
Gender Female
Nationality Indian
Contact numbers 08961499235,
Email drpriyankaci@gmail.com

Address for communication C/4/61 Vishesh Khand Gomtinagar, Lucknow-226010

	Degree/Work experience/year of completion	Duration	Institute
1	Master of Surgery (Gynaecology and Obstetrics) /2011	3 years	Institute of Post Graduate Medical Education & Research ,Kolkata, India
2	Diploma in Epidemiology /2015	1 year	Public Health Foundation of India, New Delhi, IIPH Delhi
3	M.B.B.S (Bachelor of medicine & Bachelor of surgery) /2007	6 & 1/2 years	King George's Medical University
4	Senior Residency in Obstetrics and Gynaecology/2012- 2013 Performed emergency and elective obstetric and gynaecological procedures independently	1 years	Postgraduate Institute of Medical Science and Research, ESI Hospital, Kolkata
5	Senior Residency in Gynaecological Oncology /2013-2016 Trained in colposcopy , LEEP & cryotherapy procedures and practicing the same for past 2 years. Performed various oncological surgical procedures under supervision and independently, radical hysterectomy , staging laparotomy, radical vaginectomy and radical vulvectomy.	3 years	Chittaranjan National Cancer Institute, Kolkata India

Training faculty in workshops on Colposcopy and LEEP procedures held at Chittaranjan National Cancer Institute, Kolkata

6	<p>Specialist Obstetrician and Gynaecologist with National Rural Health Mission at the CHC level- July 2017- December 2017 Performed obstetric procedures and cervical cancer and breast cancer screening at the community level.</p>	6 months	Community Health Centre Maal, Lucknow
7	<p>Assistant Professor department of Gynaecological Oncology Establishment and development of the department of the upcoming institute</p>	Since March 2017 & continuing	Super Specialty Cancer Institute, C.G. City, Lucknow

Publications

Sr No	Article	Journal
1	<p>Mittal S, Ghosh I, Banerjee D, Singh P, Biswas J, Nijhawan R, Srinivasan R, Ray C, Basu P. Reproducibility of cervical intraepithelial neoplasia diagnosis on histological review of cervical punch biopsies from a visual inspection with acetic acid and HPV detection-based screening program. Int J Gynaecol Obstet. 2014 Sep;126(3):227-31. doi: 10.1016/j.ijgo.2014.03.037. Epub 2014 May 29. PubMed PMID: 24947603</p>	International Journal of Gynaecological Oncology 2014

- | | | |
|---|--|---|
| 2 | Basu P, Mittal S, Banerjee D, Singh P, Panda C, Dutta S, Mandal R, Das P, Biswas J, Muwonge R, Sankaranarayanan R. Diagnostic accuracy of VIA and HPV detection as primary and sequential screening tests in a cervical cancer screening demonstration project in India. Int J Cancer. 2015 Aug 15;137(4):859-67. doi: 10.1002/ijc.29458. Epub 2015 Feb 12. PubMed PMID: 25631198. | International Journal of Cancer 2015 |
| 3 | Ghosh I, Mittal S, Banerjee D, Singh P, Dasgupta S, Chatterjee S, Biswas J, Panda C, Basu P. Study of accuracy of colposcopy in VIA and HPV detection-based cervical cancer screening program. Aust N Z J Obstet Gynaecol. 2014 Dec;54(6):570-5. doi: 10.1111/ajo.12282. PubMed PMID: 25476810 | Australia New Zealand Journal of Obstetrics & Gynaecology 2014 54: 570–575 DOI: 10.1111/ajo.12282 |
| 4 | Chapter- Screening for Cervical Cancer | Book- Screening in Obstetrics & Gynaecology, Management of Abnormality

Jaypee Publications
Editor Alka Pandey |
| 5 | Experience with women having uterine cancer in Eastern India: a hospital based study | International Journal of Reproduction, Contraception, Obstetrics & Gynecology |
| 6 | Is fear of COVID-19 influencing cancer patients to report for follow-up? experience from a tertiary care oncology center in eastern India | International Journal of Reproduction, Contraception, Obstetrics & Gynecology |

Research Projects/ Trials participated in

1. Phase II placebo-controlled study of VGX-3100, (HPV16 E6/E7, HPV 18 E6/E7 DNA Vaccine) delivered IM followed by electroporation (EP) with CELLECTRAÒ-5P for the treatment of biopsy-proven CIN 2/3 or CIN 3 with documented HPV-16 or 18 (Role: unblinded co-investigator, duration 3 years contributed 2 years)

2. Prevalence, Genotype Distribution of HPV in Cervical Infection, and its Attribution to Cervical Intraepithelial Neoplasia and Cervical Cancer in Indian Women; Protocol Code: HPV-Epi-001 (Role: Co Investigator duration 1 year 2015-2016)
3. Performance of APTIMA HPV mRNA Test in Cervical Cancer Screening in Indian Population (Role: Colposcopist, Duration 3 years, contributed 2 years 2014-2016)
4. Cervical Cancer Prevention & Control Initiative.(C.P.C.I) (Role: Co-investigator Duration 5 years contributed 3 years)
5. Evaluation of Gynocular as a field colposcope to detect cervical neoplasia in a VIA and HPV DNA detection based screening program(Co- investigator, Duration 1, 2015-2016)

S.No.	Name of Referee	Designation	Email Id	Period spent with the referee
1	Dr. Partha Basu	Medical Officer section of early detection and prevention IARC, France	BasuP@iarc.fr	2 and half years as senior resident Gynecological Oncology at Chittaranjan National Cancer Institute, Kolkata
2	Dr. Ranajit Mandal	Associate Professor, Gynecological oncology, Chittaranjan National Cancer Institute, Kolkata	kranajitmandal@yahoo.co.in	3 years as senior resident Gynecological Oncology at Chittaranjan National Cancer Institute, Kolkata
3	Dr. Shaleen Kumar	Director Super Speciality Cancer Institute & Hospital	shaleenkr@yahoo.com	2 & half year as Assistant Professor Gynecological Oncology at Super Speciality Cancer Institute & Hospital, Lucknow.

S. No	Name of Society	Duration of Membership
1	Association of Gynecological Oncologists of India (AGOI)	2015 to present
2	Asia Oceania research organisation on Genital Infections & Neoplasia(AOGIN) India	2014 to present
3	Kolkata Gynecological Oncology Trial Group(KolGOTrg)	March 2019 to present

Focus Areas for next 5 years:

1. Developing cost effective and time saving SOPs for the management of such cancers that are applicable to resource limited and socioeconomically challenged sections of the population.
2. Early detection of Gynecological cancers.

Goal for next 5 years:

1. To develop a robust team for evidence and audit based management of gynaecological cancers that can provide cancer care in the Institute presently working.